<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764010</url>
  </required_header>
  <id_info>
    <org_study_id>175</org_study_id>
    <nct_id>NCT00764010</nct_id>
  </id_info>
  <brief_title>Diet and Omega-3 Intervention Trial on Atherosclerosis</brief_title>
  <acronym>DOIT</acronym>
  <official_title>Diet and Omega-3 Intervention Trial on Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ultrasound Laboratory at Malmoe University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Retail Company RIMI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cardiovascular Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was actuated to evaluate the effects of a 3-year intervention with diet and/or very
      long chain omega-3 (VLC n-3 PUFA), in a randomized 2x2 factorial design on the progression of
      atherosclerosis in a high risk population. A total of 563 elderly men were included and
      randomized to receive usual care and VLC n-3 placebo capsules (control group), dietary advice
      and VLC n-3 placebo capsules, usual care and VLC n-3 capsules, and finally both VLC n-3
      capsules and dietary advice.

      The evaluation of atherosclerosis were i) ultrasound measurement of carotid intima media
      thickening ii) pulse wave propagation time iii) circulating biomarkers of atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The basis for recruitment was a follow up of subjects participating in the Oslo Diet and Anti
      Smoking Study (1972-1977) characterised as hypercholesterolemic in 1972.

      Measurements of the outcome variables were performed at baseline and after 36 m; blood
      sampling also after 6 and 18 m.

      In addition to the main outcome variables, a biobank was established for future analyses.

      Clinical events were also recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variables of atherosclerosis progression: IMT, Pulse Wave Propagation Time, Circulating biomarkers</measure>
    <time_frame>1997-2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetical influence of the intervention principles (&quot;Nutrigenetics&quot;)</measure>
    <time_frame>1997-2010</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">563</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No dietary counseling, placebo capsules for omega-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary counseling, placebo capsules for omega-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No dietary counseling, omega-3 capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary counseling and omega-3 capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>No dietary counseling and omega-3 capsules</intervention_name>
    <description>Omega-3 2.4 g/day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 capsules and dietary counseling</intervention_name>
    <description>Omega-3 2.4 g/day and Mediterranean-like diet</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary counseling, placebo capsules for omega-3</intervention_name>
    <description>Mediterranean-like diet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly men with long standing hypercholesterolemia (cholesterol &gt; 6.45 mmol/L and &lt;
             8.00 mmol/L) with or without coronary heart disease.

        Exclusion Criteria:

          -  Cholesterol &gt; 8.00 mmol/L, blood pressure &gt; 170/100

          -  Uncontrolled hypertension

          -  Socially or otherwise unsuitable subjects

          -  Anticipated non compliance

          -  Other major non cardiac illness expected to reduce life expectancy or interfere with
             study participation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>64 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Arnesen, M.D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullev√•l University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Harald Arnesen, Professor of Medicine</name_title>
    <organization>Ulleval University Hospital, Oslo, Norway</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

